Method Transfer Failure for innovative delivery systems: how to document for FDA/EMA/MHRA review
Identifying the early warnings of method transfer failure is vital. Common symptoms include:Click to read the full article.
Tips for Advanced & Novel Drug Delivery Systems
Cpv Trending Gap after formulation change: decision tree for lab vs manufacturing root cause
Identifying the symptoms that indicate a potential Cpv trending gap is the first step in effective investigation. Common signals you may encounter include:Click to read the full article.
Scale-Up Failure after formulation change: control strategy build-out for inspections
Understanding the symptoms or signals that indicate a scale-up failure is the first step in initiating an investigation. Common signs to look for during production or quality control include:Click to…
Oos Release Profile after formulation change: how to document for FDA/EMA/MHRA review
Documenting OOS Release Profiles Following Formulation Changes: A Guide for Compliance and Investigation In the pharmaceutical manufacturing landscape, deviations such as Out-of-Specification (OOS) results post-formulation change present complex challenges. These…
Cpv Trending Gap for nanoformulations: decision tree for lab vs manufacturing root cause
Detecting and documenting symptoms or signals is crucial for initiating an investigation into Cpv trending gaps for nanoformulations. Common indicators include:Click to read the full article.
E&L Failure for long-acting injectables: how to document for FDA/EMA/MHRA review
Symptoms of E&L failures often manifest as deviations in product quality or laboratory test results, primarily during stability testing or routine quality control measures. Some key signals include:Click to read…
Control Strategy Weakness after formulation change: decision tree for lab vs manufacturing root cause
Identifying symptoms or signals is paramount in recognizing a control strategy weakness following a formulation change. Symptoms may manifest as Out of Specification (OOS) results, deviations from established batch records,…
Cpv Trending Gap during tech transfer: control strategy build-out for inspections
The first step in addressing a Cpv trending gap is identifying symptoms or signals that indicate potential issues during the tech transfer process. Observational data collected from both the manufacturing…
Control Strategy Weakness during lifecycle management: control strategy build-out for inspections
Identifying symptoms or signals of control strategy weaknesses can be pivotal in early detection. Symptoms may include:Click to read the full article.
Ivivc Mismatch for modified release platforms: how to document for FDA/EMA/MHRA review
Identifying symptoms related to an IVIVC mismatch is a critical first step in the investigation process. These symptoms may manifest during various development stages through unexpected findings in stability data,…
Ivivc Mismatch during PAI readiness: regulatory-ready investigation and CAPA plan
The first step in identifying an Ivivc mismatch is recognizing the symptoms or signals that indicate a deviation has occurred. Common signals may include:Click to read the full article.
Scale-Up Failure for long-acting injectables: risk assessment and validation impact analysis
Identifying the symptoms of scale-up failure is critical for timely intervention. Common signals may manifest during various manufacturing stages, such as:Click to read the full article.